When BioNTech and Pfizer announced their COVID-19 vaccine partnership in early 2020, the world was desperate for good news. Hospitals overflowed. Case counts climbed by the hour. No one knew how long development would take—or whether it would work at all. Then, less than a year later, the two companies delivered a vaccine to millions of arms, setting a record for speed that researchers are still trying to understand. As of September 2025, that single partnership has put 5 billion doses into people worldwide. The secret wasn't just scientific discovery. It was something far more human.
A new study from the Georgia Institute of Technology suggests that when biotech firms and pharmaceutical giants work together, cultural alignment predicts success more reliably than size or resources. Manpreet Hora, senior associate dean for programs and professor of operations management in Georgia Tech's Scheller College of Business, analyzed nearly 300 biotech-pharma partnerships to understand why some drugs make it to patients and others stall indefinitely. His findings, published in the journal Production and Operations Management, reveal a pattern hidden in plain sight: companies that share similar experience levels and ways of working move faster. Those that don't face slowdowns, unclear roles, and eroded momentum.
"If you are a patient, this process is out of your control," Hora said. "In some cases, it can cost lives."
The implications stretch well beyond the pandemic. Drug development often depends on handoffs—small biotech firms generate early discoveries, larger pharmaceutical companies run trials and navigate regulators, and together they bring products to market. But complications arise when partners lack compatible rhythms. Decision-making stalls. Expectations misalign. Promising therapies never arrive where they're needed most.
Hora compares the stakes to a high-stakes business pitch. "It's like going on Shark Tank—just because someone is offering money doesn't mean they're the right partner."
The Pfizer-BioNTech partnership succeeded, the research suggests, precisely because both companies approached the work the same way. BioNTech was a small startup with years of mRNA expertise. Pfizer was one of the world's largest pharmaceutical companies. They differed wildly in scale. But they shared a sense of purpose. Pfizer's chairman and CEO, Albert Bourla, described the collaboration as "world class" and attributed its success to shared values: "I think it was because both companies had developed very similar cultures…We were both really very purpose-driven."
For patients waiting on experimental treatments, the lesson is clear. Science can open the door—but culture determines whether a drug ever walks through it.